Low-dose SoluMatrix diclofenac: a review of safety across two Phase III studies in patients with acute and osteoarthritis pain

Bibliography

• Pogatzki-Zahn E, Chandrasena C, Schug SA. Nonopioid analgesics for postoperative pain management. Curr Opin Anaesthesiol 2014;27(5):513-19
   PubMed Web of Science ®Google Scholar
• Argoff CE. Recent developments in the treatment of osteoarthritis with NSAIDs. Curr Med Res Opin 2011;27(7):1315-27
   PubMed Web of Science ®Google Scholar
• Derry P, Derry S, Moore RA, McQuay HJ. Single dose oral diclofenac for acute postoperative pain in adults. Cochrane Database Syst Rev 2009(2):CD004768
   Google Scholar
• Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis & Rheumatism 2000;43(2):378-85
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10(2):e1001388
   PubMed Web of Science ®Google Scholar
• Todd PA, Sorkin EM. Diclofenac sodium. Drugs 1988;35(3):244-85
   PubMed Web of Science ®Google Scholar
• Voltaren Enteric Coated Tablets Prescribing Information 2011. Available from: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=2884 [Last accessed 27 December 2013]
   Google Scholar
• Brogden RN, Heel RC, Pakes GE, et al. Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 1980;20(1):24-48
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics PL. Diclofenac potassium 50 mg tablets. 2012. Available from: http://www.medicines.org.uk/emc/PIL.29260.latest.pdf [Last accessed 27 December 2014]
   Google Scholar
• Cambia Prescribing Information 2009. Available from: http://www.cambiarx.com/wp-content/uploads/Cambia-Prescribing-Information.pdf [Last accessed 18 November 2014]
   Google Scholar
• Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32(3 Suppl 1):33-42
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19(7):745-51
   PubMedGoogle Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8(9):e1001098
   PubMed Web of Science ®Google Scholar
• Riera-Guardia N, Castellsague J, Calingaert B, et al. The SOS Project: Nonsteroidal Anti-Inflammatory Drugs and Upper Gastrointenstinal Complications. Meta-Analysis of Epidemiological Studies. Int Conf Pharm 2010;Brighton, United Kingdom 2010
   Google Scholar
• Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011;89(6):855-66
   PubMed Web of Science ®Google Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769-79
   PubMed Web of Science ®Google Scholar
• Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin 2010;26(7):1715-31
   PubMed Web of Science ®Google Scholar
• Verrico MM, Weber RJ, McKaveney TP, et al. Adverse Drug Events Involving COX-2 Inhibitors. Ann Pharmacother 2003;37(9):1203-13
   PubMed Web of Science ®Google Scholar
• Gibofsky A, Hochberg MC, Jaros MJ, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. Curr Med Res Opin 2014;30(9):1883-93
   PubMed Web of Science ®Google Scholar
• Watson R. European Medicines Agency gives favourable ruling on NSAIDs. BMJ 2006;333(7574):873
   PubMed Web of Science ®Google Scholar
• Voltaren XR Prescribing Information 2009. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/voltaren_xr.pdf [Last accessed 27 December 2014]
   Google Scholar
• Cataflam Prescribing Information. 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020142s021s022lbl.pdf [Last accessed 05 December 2014]
   Google Scholar
• Zipsor Full Prescribing Information. 2012. Available from: http://www.zipsor.com/files/PI.pdf [Last accessed 18 November 2014]
   Google Scholar
• ARTHROTEC medical guide. Diclofenac sodium/misoprostol tablets 2013. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=526 [Last accessed 20 February 2014]
   Google Scholar
• Pennsaid Prescribing Information 2009. Available from: http://www.pennsaid.com/files/PENNSAID_Prescribing_Information.pdf [Last accessed 27 December 2014]
   Google Scholar
• Flector Prescribing Information 2011. Available from: http://www.flectorpatch.com/pdf/Flector_PI_M110029.pdf [Last accessed 18 November 2014]
   Google Scholar
• Iroko Pharmaceuticals L; Information for the Pharmacist. Introducing ZORVOLEXTM (diclofenac), the First Lower-Dose NSAID Developed Using SoluMatrix Fine Particle TechnologyTM. 2013. Available from: https://s3.amazonaws.com/pharmacytimes/d_media/_pdf/ZORVOLEX-FINAL-NOV13.pdf [Last accessed 15 August 2014]
   Google Scholar
• Low-dose diclofenac (Zorvolex) for pain. The medical letter 2014;56(1437)
   Google Scholar
• Zorvolex Full Prescribing Information. 2013. Available from: https://www.iroko.com/wp-content/uploads/2013/10/Zorvolex_PI_10-18-2013.pdf [Last accessed 08 November 2014]
   Google Scholar
• Gibofsky A, Silberstein S, Argoff C, et al. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Post Graduate Medicine 2013;125(5):130-8
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Saarelainen S, Gronroos JM, et al. Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. Scand J Gastroenterol 2007;42(8):923-32
   PubMed Web of Science ®Google Scholar
• Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005;45(3):531-9
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27(14):1657-63
   PubMed Web of Science ®Google Scholar
• Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, et al. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156(21):2433-9
   PubMed Web of Science ®Google Scholar
• Odom DM, Mladsi DM, Saag KG, et al. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther 2014;36(6):906-17
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465-74
   PubMed Web of Science ®Google Scholar
• Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta 1987;921(3):502-11
   PubMed Web of Science ®Google Scholar
• Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999;96(13):7563-8
   PubMed Web of Science ®Google Scholar
• Patrignani P, Patrono C. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochim Biophys Acta 2015;1851(4):422-32
   PubMed Web of Science ®Google Scholar
• Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343(8905):1075-8
   PubMed Web of Science ®Google Scholar
• Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108(1):7-13
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-8
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-102
   PubMed Web of Science ®Google Scholar
• Altman R, Daniels S, Young CL. Indomethacin submicron particle capsules provide effective pain relief in patients with acute pain: a phase 3 study. Phys Sportsmed 2013;41(4):7-15
   PubMed Web of Science ®Google Scholar
• Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107(3):379-86
   PubMed Web of Science ®Google Scholar
• Lanas A. Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy. Rev Gastroenterol Mex 2004;69(4):251-60
   PubMedGoogle Scholar
• de Melo Gomes JA. The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy. Scand J Rheumatol Suppl 1992;96:23-31
   PubMedGoogle Scholar
• McKenna F. Diclofenac/misoprostol: the European clinical experience. J Rheumatol Suppl 1998;51:21-30
   PubMedGoogle Scholar
• Sugano K, Kinoshita Y, Miwa H, et al. Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. BMC Gastroenterol 2013;13:54
   PubMedGoogle Scholar
• Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(4):241-9
   PubMed Web of Science ®Google Scholar
• Ares JJ, Outt PE. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des 1998;4(1):17-36
   PubMed Web of Science ®Google Scholar
• Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123(5):344-50
   PubMed Web of Science ®Google Scholar
• Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103(10):2465-73
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011;97(10):797-802
   PubMed Web of Science ®Google Scholar
• Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34(11-12):1269-81
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Abdulhak AB, Riaz M, et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One 2013;8(3):e56498
   PubMedGoogle Scholar
• Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012;7(12):e50836
   PubMed Web of Science ®Google Scholar
• Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124(2):288-92
   PubMed Web of Science ®Google Scholar
• Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 2013;19(12):1861-76
   PubMed Web of Science ®Google Scholar
• Huang C, Lu B, Fan YH, et al. Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury. World J Gastroenterol 2014;20(31):11012-18
   PubMed Web of Science ®Google Scholar
• Scheiman JM. Prevention of damage induced by aspirin in the GI tract. Best Pract Res Clin Gastroenterol 2012;26(2):153-62
   PubMed Web of Science ®Google Scholar
• Voltaren Gel 1% Prescribing Information. 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022122s006lbl.pdf [Last accessed 1 November 2014]
   Google Scholar
• Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312(7046):1563-6
   PubMed Web of Science ®Google Scholar
• Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27(6):411-20
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Public Health Advisory - FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 2005. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.html [Last accessed 13 March 2014]
   Google Scholar
• Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52(20):1628-36
   PubMed Web of Science ®Google Scholar
• Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012;35(12):1127-46
   PubMed Web of Science ®Google Scholar
• Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. Postgrad Med 2012;124(1):117-23
   PubMed Web of Science ®Google Scholar
• Daniels SE, Baum DR, Clark F, et al. Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain. Curr Med Res Opin 2010;26(10):2375-84
   PubMed Web of Science ®Google Scholar
• Riff DS, Duckor S, Gottlieb I, et al. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Clin Ther 2009;31(10):2072-85
   PubMed Web of Science ®Google Scholar
• Bakshi R. Comparative efficacy and tolerability of two diclofenac formulations in the treatment of painful osteoarthritis. Br J Clin Pract 1996;50(6):294-7
   PubMedGoogle Scholar
• Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000;160(19):2947-54
   PubMed Web of Science ®Google Scholar
• Sikes DH, Agrawal NM, Zhao WW, et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14(10):1101-11
   PubMed Web of Science ®Google Scholar
• Desjardins PJ, Olugemo K, Solorio D, et al. Pharmacokinetic Properties and Tolerability of Low-dose SoluMatrix Diclofenac. Clin Ther 2015;37(2):448-61
   PubMed Web of Science ®Google Scholar
• Riad LE, Sawchuk RJ, McAlary MM, et al. Effect of Food on the Multiple-Peak Behavior After a Single Oral Dose of Diclofenac Sodium Slow-Release Tablet in Humans. Am J Ther 1995;2(4):237-42
   PubMedGoogle Scholar
• Marzo A, Dal Bo L, Verga F, et al. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneimittelforschung 2000;50(1):43-7
   PubMed Web of Science ®Google Scholar
• Lissy M, Scallion R, Stiff DD, et al. Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet. Expert Opin Pharmacother 2010;11(5):701-8
   PubMed Web of Science ®Google Scholar
• Reiner V, Reiner A, Reiner G, et al. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittelforschung 2001;51(11):885-90
   PubMed Web of Science ®Google Scholar
• Rusca A, Mautone G, Sun S, et al. Comparison of plasma pharmacokinetics of FLECTOR Patch (diclofenac epolamine topical patch) and oral Voltaren (diclofenac sodium enteric-coated tablets) in healthy volunteers. J Pain 2008;9(4):45
   PubMedGoogle Scholar
• Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin 2008;24(10):2967-92
   PubMed Web of Science ®Google Scholar
• Emery P, Koncz T, Pan S, et al. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. Clin Ther 2008;30(1):70-83
   PubMed Web of Science ®Google Scholar